Filing Flows

Filing Flows › 8-K events › Aura Biosciences

Aura Biosciences: results of operations

Form 8-K filed Nov 9, 2026 · items 2.02, 8.01

FDA decisionsAura Biosciences Reports Third Quarter 2026 Financial Results and Recent Business Highlights

What the filing says

Aura Biosciences Reports Third Quarter 2026 Financial Results and Recent Business Highlights Phase 3 CoMpass trial on track for topline data in 2H 2027; all participants have completed treatment visits

Read the filing on SEC EDGAR →

What usually followsAcross 69,249 8-Ks reporting Item 2.02 (results of operations) in our universe, the stock's median move the next session was +0.2% (typical size ±3.6%, up 51% of the time); over the following 21 sessions, +1.2%. Item 8.01: +0.1% next session across 44,918. Every item ranked →

Other recent fda decisions

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.